BRPI0510803A - composto, composição farmacêutica, artigo de fabricação, métodos de tratar ou prevenir a formação, deposição, acúmulo ou persistência de fibrilas de amilóide e de fibrilas de sinucleìna, e de tratar, prevenir ou melhorar um ou mais sintomas de uma doença amilóide ou uma sinucleinopatia em um mamìfero, e, uso do composto - Google Patents
composto, composição farmacêutica, artigo de fabricação, métodos de tratar ou prevenir a formação, deposição, acúmulo ou persistência de fibrilas de amilóide e de fibrilas de sinucleìna, e de tratar, prevenir ou melhorar um ou mais sintomas de uma doença amilóide ou uma sinucleinopatia em um mamìfero, e, uso do compostoInfo
- Publication number
- BRPI0510803A BRPI0510803A BRPI0510803-9A BRPI0510803A BRPI0510803A BR PI0510803 A BRPI0510803 A BR PI0510803A BR PI0510803 A BRPI0510803 A BR PI0510803A BR PI0510803 A BRPI0510803 A BR PI0510803A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- preventing
- compound
- fibrils
- amyloid
- Prior art date
Links
- 206010002022 amyloidosis Diseases 0.000 title abstract 4
- 230000015572 biosynthetic process Effects 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 208000032859 Synucleinopathies Diseases 0.000 title abstract 2
- 238000009825 accumulation Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002688 persistence Effects 0.000 title abstract 2
- 102000001049 Amyloid Human genes 0.000 title 1
- 108010094108 Amyloid Proteins 0.000 title 1
- 241000124008 Mammalia Species 0.000 title 1
- 102000019355 Synuclein Human genes 0.000 title 1
- 108050006783 Synuclein Proteins 0.000 title 1
- 230000035508 accumulation Effects 0.000 title 1
- 230000008021 deposition Effects 0.000 title 1
- 208000024891 symptom Diseases 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 abstract 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- PLOPBXQQPZYQFA-AXPWDRQUSA-N amlintide Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)CSSC1)[C@@H](C)O)C(C)C)C1=CC=CC=C1 PLOPBXQQPZYQFA-AXPWDRQUSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000835 fiber Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57066904P | 2004-05-12 | 2004-05-12 | |
| US62952504P | 2004-11-18 | 2004-11-18 | |
| PCT/US2005/016677 WO2005113489A1 (en) | 2004-05-12 | 2005-05-12 | Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0510803A true BRPI0510803A (pt) | 2007-11-06 |
Family
ID=34969702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0510803-9A BRPI0510803A (pt) | 2004-05-12 | 2005-05-12 | composto, composição farmacêutica, artigo de fabricação, métodos de tratar ou prevenir a formação, deposição, acúmulo ou persistência de fibrilas de amilóide e de fibrilas de sinucleìna, e de tratar, prevenir ou melhorar um ou mais sintomas de uma doença amilóide ou uma sinucleinopatia em um mamìfero, e, uso do composto |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7745490B2 (https=) |
| EP (1) | EP1751097B1 (https=) |
| JP (1) | JP5203701B2 (https=) |
| KR (1) | KR101168451B1 (https=) |
| AT (1) | ATE453617T1 (https=) |
| AU (1) | AU2005245412B2 (https=) |
| BR (1) | BRPI0510803A (https=) |
| CA (1) | CA2566090C (https=) |
| DE (1) | DE602005018634D1 (https=) |
| DK (1) | DK1751097T3 (https=) |
| ES (1) | ES2337162T3 (https=) |
| IL (1) | IL179160A (https=) |
| MX (1) | MXPA06012603A (https=) |
| NO (1) | NO20065717L (https=) |
| NZ (1) | NZ551589A (https=) |
| RU (1) | RU2381213C2 (https=) |
| SG (1) | SG137850A1 (https=) |
| WO (1) | WO2005113489A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090124690A1 (en) * | 2000-04-03 | 2009-05-14 | Alberte Randall S | Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins |
| US20070208087A1 (en) * | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
| CA2647543A1 (en) * | 2006-03-29 | 2007-11-08 | Foldrx Pharmaceuticals, Inc. | Inhibition of alpha-synuclein toxicity |
| WO2009111611A2 (en) * | 2008-03-05 | 2009-09-11 | Proteotech Inc. | Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes |
| EP2098226A1 (de) * | 2008-03-06 | 2009-09-09 | Forschungsverbund Berlin e.V. | AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten |
| EP2554163A4 (en) * | 2010-03-26 | 2013-07-17 | Univ Hokkaido Nat Univ Corp | THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES |
| US20120251448A1 (en) * | 2011-03-03 | 2012-10-04 | Hefti Franz F | Compounds for Use in the Detection of Neurodegenerative Diseases |
| CN118206529A (zh) | 2017-09-04 | 2024-06-18 | C4医药公司 | 二氢苯并咪唑酮 |
| US10799551B2 (en) | 2017-09-25 | 2020-10-13 | Amorepacific Corporation | Composition for enhancing cognitive function comprising green tea extract which has modified amounts of ingredients |
| KR102011033B1 (ko) * | 2017-09-25 | 2019-08-14 | (주)아모레퍼시픽 | 성분 함량이 변화된 녹차 추출물을 포함하는 인지기능 개선용 조성물 |
| US20220041591A1 (en) * | 2018-10-19 | 2022-02-10 | Auckland Uniservices Limited | Compounds for treating diabetes and/or related conditions |
| WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
| WO2023224893A1 (en) * | 2022-05-20 | 2023-11-23 | Merck Sharp & Dohme Llc | Inhibitors of msba as antibiotics, pharmaceutical compositions, and uses thereof |
| CN117682973B (zh) * | 2022-09-26 | 2026-03-20 | 中国药科大学 | 磺酰胺类化合物及其医药用途 |
| EP4686725A1 (en) | 2024-08-02 | 2026-02-04 | Technische Universität München, in Vertretung des Freistaats Bayern | Amyloid inhibitory peptides |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5916871A (ja) * | 1982-07-20 | 1984-01-28 | Shionogi & Co Ltd | スルホンアミド系ベンズアミド類 |
| JPS63132237A (ja) * | 1986-11-21 | 1988-06-04 | Konica Corp | 迅速処理を行なつても優れた発色性を有するハロゲン化銀写真感光材料 |
| MX9203460A (es) * | 1988-09-12 | 1992-09-01 | Upjohn Co | Nuevos analogos cc-1065 que tienen dos subunidades cpi. |
| GB8914660D0 (en) * | 1989-06-26 | 1989-08-16 | Fujisawa Pharmaceutical Co | Aniline derivatives,processes for production thereof and pharmaceutical compositions comprising the same |
| JPH04285955A (ja) * | 1991-03-14 | 1992-10-12 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| RU2236220C2 (ru) * | 1998-05-22 | 2004-09-20 | Аванир Фармасьютикэлз | Аналоги бензимидазола в качестве понижающих регуляторов ige |
| OA11665A (en) * | 1998-10-22 | 2004-12-08 | Neurosearch As | Substituted phenyl derivatives, their preparation and use. |
| JP4623453B2 (ja) * | 1999-10-14 | 2011-02-02 | 旭化成イーマテリアルズ株式会社 | アミドフェノール化合物 |
| MXPA03011201A (es) * | 2001-06-07 | 2004-02-26 | Lilly Co Eli | Moduladores de receptores activados por proliferadores de persoxisomas. |
| PT2527315E (pt) * | 2002-05-31 | 2014-06-24 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
| WO2004026264A2 (en) * | 2002-09-20 | 2004-04-01 | Genelabs Technologies, Inc. | Novel aromatic compounds possessing antifungal or antibacterial activity |
-
2005
- 2005-05-12 BR BRPI0510803-9A patent/BRPI0510803A/pt not_active IP Right Cessation
- 2005-05-12 SG SG200717673-8A patent/SG137850A1/en unknown
- 2005-05-12 NZ NZ551589A patent/NZ551589A/en not_active IP Right Cessation
- 2005-05-12 ES ES05749770T patent/ES2337162T3/es not_active Expired - Lifetime
- 2005-05-12 RU RU2006143761/04A patent/RU2381213C2/ru not_active IP Right Cessation
- 2005-05-12 JP JP2007513368A patent/JP5203701B2/ja not_active Expired - Fee Related
- 2005-05-12 AT AT05749770T patent/ATE453617T1/de active
- 2005-05-12 KR KR1020067026028A patent/KR101168451B1/ko not_active Expired - Fee Related
- 2005-05-12 WO PCT/US2005/016677 patent/WO2005113489A1/en not_active Ceased
- 2005-05-12 MX MXPA06012603A patent/MXPA06012603A/es active IP Right Grant
- 2005-05-12 CA CA2566090A patent/CA2566090C/en not_active Expired - Fee Related
- 2005-05-12 EP EP05749770A patent/EP1751097B1/en not_active Expired - Lifetime
- 2005-05-12 DK DK05749770.3T patent/DK1751097T3/da active
- 2005-05-12 AU AU2005245412A patent/AU2005245412B2/en not_active Ceased
- 2005-05-12 DE DE602005018634T patent/DE602005018634D1/de not_active Expired - Lifetime
-
2006
- 2006-01-09 US US11/328,748 patent/US7745490B2/en not_active Expired - Fee Related
- 2006-11-09 IL IL179160A patent/IL179160A/en not_active IP Right Cessation
- 2006-12-12 NO NO20065717A patent/NO20065717L/no not_active Application Discontinuation
-
2008
- 2008-08-29 US US12/201,183 patent/US20090060838A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20065717L (no) | 2007-02-08 |
| RU2381213C2 (ru) | 2010-02-10 |
| ATE453617T1 (de) | 2010-01-15 |
| EP1751097B1 (en) | 2009-12-30 |
| JP2007537287A (ja) | 2007-12-20 |
| US7745490B2 (en) | 2010-06-29 |
| SG137850A1 (en) | 2007-12-28 |
| RU2006143761A (ru) | 2008-06-20 |
| MXPA06012603A (es) | 2007-04-12 |
| EP1751097A1 (en) | 2007-02-14 |
| NZ551589A (en) | 2009-10-30 |
| US20060199838A1 (en) | 2006-09-07 |
| WO2005113489A1 (en) | 2005-12-01 |
| JP5203701B2 (ja) | 2013-06-05 |
| IL179160A (en) | 2011-04-28 |
| ES2337162T3 (es) | 2010-04-21 |
| DE602005018634D1 (de) | 2010-02-11 |
| US20090060838A1 (en) | 2009-03-05 |
| CA2566090C (en) | 2013-07-23 |
| DK1751097T3 (da) | 2010-05-10 |
| AU2005245412B2 (en) | 2011-08-04 |
| KR101168451B1 (ko) | 2012-07-25 |
| IL179160A0 (en) | 2007-03-08 |
| CA2566090A1 (en) | 2005-12-01 |
| KR20070015612A (ko) | 2007-02-05 |
| AU2005245412A1 (en) | 2005-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0510803A (pt) | composto, composição farmacêutica, artigo de fabricação, métodos de tratar ou prevenir a formação, deposição, acúmulo ou persistência de fibrilas de amilóide e de fibrilas de sinucleìna, e de tratar, prevenir ou melhorar um ou mais sintomas de uma doença amilóide ou uma sinucleinopatia em um mamìfero, e, uso do composto | |
| AR029383A1 (es) | Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes | |
| ECSP055633A (es) | Nuevos derivados de benzoimidazolutiles como angentes antiproliferativos | |
| BRPI0406717A (pt) | Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção | |
| BRPI0911476A2 (pt) | compostos ativadores de glicoquinase de piridazinona, composição farmaceutica, uso dos compostos, método para tratamento de uma enfermidade e/ou distúbio metabólico e processo para a preparação dos compostos | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| AR024197A1 (es) | Compuesto derivado de succinamida, composicion farmaceutica que lo comprende y uso de dicho compuesto en la fabricacion de un medicamento util para eltratamiento de afecciones neurologicas | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| BR0312216A (pt) | Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito que sofre de uma doença ou condição patológica e combinação de produto | |
| SE0104334D0 (sv) | Therapeutic agents | |
| EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
| EA200201277A1 (ru) | Замещенные бициклические производные для лечения аномального роста клеток | |
| BR0108610A (pt) | Compostos azapolicìclicos condensados com arila | |
| BR9807876A (pt) | Compostos heterocìclicos e seu uso para inibição de peptìdeo beta-amilóide | |
| BR0013311A (pt) | Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor | |
| ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
| AR056575A1 (es) | Compuesto de (alfa)-aminocarboxiamida que es 5-(4-[[(2-fluorofenil) metil] oxi] fenil)prolinamida, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y proceso para prepararlo | |
| BR0213138A (pt) | Métodos de tratar ou prevenir mal de alzheimer e uma doença distinguida por depósito de beta-amilóide no cérebro, de tratar um paciente que tenha, ou de prevenir um paciente de contrair uma doença ou condição, de produzir um complexo de beta-secretase e de inibir a produção de placa beta-amilóide em um animal, composição e uso de um composto | |
| BR0016217A (pt) | Composto, processo para prepará-lo, composição farmacêutica, e, uso do composto | |
| BR9909086A (pt) | Derivados de piperidinila e n-amidinopiperidinila | |
| BR0317433A (pt) | Derivados bicìclicos para o tratamento do crescimento celular anormal | |
| BR9910637A (pt) | Composto da série da benzofuroxana usada para distúrbios cardiovasculares, processos para a preparação dos derivados de benzofuroxana, e para a preparação de 5 (6)-[(2,3-diidróxi propilóxi)-carbonil] benzofuroxana, uso do composto, composição farmacêutica, processo para a preparação da mesma, e, processo para o tratamento de um mamìfero, incluindo um ser humano, de doença cardìacas da coronária. | |
| CL2008003378A1 (es) | Compuestos derivados de 9,10-dioxo-2-antracen-carboxilico sustituidos; procedimiento de preparacion de los compuestos; composicion farmaceutica; y su uso en el tratamiento de condiciones que son influenciadas por citoquinas pro-inflamatorias de la familia il-1, particularmente enfermedades inflamatorias y autoinmunes. | |
| TW200740795A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | |
| TW200800962A (en) | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |